CAS 1448221-05-3

Vanucizumab

CAS : 1448221-05-3

Humanized bispecific IgG1 monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2)

Ref: 3D-CLA1362

Vanucizumab

CAS : 1448221-05-3

Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2)

Degré de pureté : 95%

Couleur et forme : Liquid

Ref: TM-T76837